Vasculitis Treatment Guidelines

Initial Treatment Strategies

The American College of Nephrology recommends initiating high-dose glucocorticoids immediately upon diagnosis, with 40-60 mg/day prednisone-equivalent or 1 mg/kg/day, always combined with immunosuppressive agents for severe disease 1, 2
For severe presentations, the Kidney International guidelines suggest administering intravenous methylprednisolone 1-3 g daily for 3-5 days as pulse therapy before transitioning to oral steroids 1, 4
Following pulse therapy, the Annals of the Rheumatic Diseases guidelines recommend initiating oral prednisone 1 mg/kg/day (maximum 60 mg/day) for all vasculitis types 1, 2, 3

The KDIGO guidelines demonstrate that reduced-dose glucocorticoids (0.5 mg/kg/day) are noninferior to high-dose (1 mg/kg/day) when combined with rituximab in patients with ANCA-associated vasculitis without severe glomerulonephritis or life-threatening alveolar hemorrhage 1
The Kidney International guidelines suggest tapering to 0.2 mg/kg/day (maximum 10 mg/day) by month 6 in patients with ANCA-associated vasculitis 1
For large vessel vasculitis, the Annals of the Rheumatic Diseases guidelines recommend initiating prednisone 40-60 mg/day (or 1 mg/kg/day) immediately to prevent blindness in GCA or vascular complications in Takayasu arteritis 2, 3

The Kidney International guidelines suggest that avacopan (C5a receptor antagonist) 30 mg twice daily is an effective alternative to prednisone in ANCA-associated vasculitis, achieving 72.3% remission versus 70.1% with prednisolone 1
The Kidney International guidelines recommend using traditional glucocorticoids in severe presentations, such as patients with eGFR <15 ml/min/1.73m² or alveolar hemorrhage requiring mechanical ventilation 1

The Kidney International guidelines suggest continuing glucocorticoid maintenance at 5-7.5 mg/day for 2 years, then reducing by 1 mg every 2 months 3
The Kidney International guidelines recommend maintaining therapy for at least 18-24 months for ANCA-associated vasculitis to prevent relapse 5, 3

The Kidney International guidelines warn that the most serious adverse events from steroids include infections, diabetes, osteoporosis, and cardiovascular complications 1, 6
The Autoimmunity Reviews guidelines suggest that high-dose pulse glucocorticoid therapy is useful for critical flares in mixed cryoglobulinemia syndrome, but chronic low-dose therapy should be avoided due to serious irreversible side effects 6

The Kidney International guidelines recommend monitoring for infections aggressively, as they are more common and severe with high-dose glucocorticoids, particularly when combined with rituximab or cyclophosphamide 1, 4
The Kidney International guidelines suggest tracking ANCA levels during treatment, as persistence or increase may predict future relapse 5, 3